The biopharma industry is full of amazing ideas, but getting funding for them and turning them into medicines for the real world is a huge challenge. As anyone in the industry knows, getting investors to back your company can be as challenging as getting the science to work and can take a significant amount of the company’s time and effort.

Two innovators in the concussion assessment space have advanced their products with new funding and new clearances. Brainscope Co. Inc. secured $35 million in capital through an intellectual property-based funding arrangement with Aon plc to expand access to and develop new applications for its EEG-based product. Syncthink Inc. received a second FDA clearance for its Eye-Sync platform for mild traumatic brain injury diagnosis.

Neumora Therapeutics Inc., a neuroscience startup aiming to launch precision medicines for brain diseases, said Oct. 7 it has raised more than $500 million, including a $100 million equity investment from Amgen Inc. and a series A financing led by Arch Venture Partners. The company launches with a portfolio of eight clinical, preclinical and discovery-stage programs from internal discovery efforts, the acquisitions of multiple private companies and a new license agreement with Amgen.

Intergalactic Therapeutics Inc. is aiming for the stars with a nonviral gene therapy platform, backed with $75 million in series A financing from life sciences venture capital firm Apple Tree Partners. While management are tongue in cheek about the name of the company, they are serious about their mission to produce a next generation of gene therapies that overcome the issues associated with marketed adeno-associated virus-based products.

Exscientia plc has raised $510.4 million in an upsized Nasdaq IPO and private funding round as it pushes forward with its artificial intelligence-based drug discovery mission. The Oxford, U.K.-based company aims to out-license some of its candidates to other companies, while saving others for its own pipeline.